- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.05. | Genelux GAAP EPS of -$0.20 | 1 | Seeking Alpha | ||
| 07.05. | GENELUX Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 19.03. | GENELUX Corp - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 19.03. | GENELUX Corp - 8-K, Current Report | 1 | SEC Filings | ||
| GENELUX Aktie jetzt für 0€ handeln | |||||
| 19.03. | Genelux GAAP EPS of -$0.86 misses by $0.01 | 2 | Seeking Alpha | ||
| 19.03. | Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | 685 | GlobeNewswire (Europe) | -- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses... ► Artikel lesen | |
| 19.03. | GENELUX Corp - 10-K, Annual Report | 2 | SEC Filings | ||
| 02.02. | GENELUX Corp - 8-K, Current Report | 4 | SEC Filings | ||
| 12.01. | Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners | 4 | GlobeNewswire (USA) | ||
| 09.01. | Weekly Buzz: ScinoPharm Gets FDA Nod; Genelux's Olvi-Vec Shows Promise; Monte Rosa Therapeutics' MRT-8102 Advances | 698 | AFX News | PARIS (dpa-AFX) - The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis.... ► Artikel lesen | |
| 08.01. | Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock | 5 | GlobeNewswire (USA) | ||
| 07.01. | Genelux kündigt öffentliches Angebot von Stammaktien an | 4 | Investing.com Deutsch | ||
| 07.01. | Genelux announces proposed public offering | 1 | Seeking Alpha | ||
| 07.01. | Genelux Corporation Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 05.01. | Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data | 4 | Investing.com | ||
| 05.01. | Genelux-Aktie: Positive Studiendaten stützen Kaufempfehlung von H.C. Wainwright | 3 | Investing.com Deutsch | ||
| 02.01. | GENELUX Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 02.01. | Genelux Corp Appoints Jason Litten CMO | 3 | RTTNews | ||
| 02.01. | Genelux appoints Jason Litten as chief medical officer | 1 | Investing.com | ||
| 02.01. | Genelux beruft Jason Litten zum neuen Chief Medical Officer | 3 | Investing.com Deutsch |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INFLARX | 2,124 | +0,95 % | InflaRx NV im Höhenflug: Was hinter dem Kursanstieg wirklich steckt - Was ich konkret unternommen habe! | ||
| REDHILL BIOPHARMA | 0,930 | +2,20 % | RedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights | 2025 was a year of tenacity, strategic transactions and building traction for RedHill
Talicia® business transformed:
Formation of Talicia Holdings Inc. (THI) and... ► Artikel lesen | |
| IMMUNIC | - | - | EQS-News: Immunic AG: Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors | Issuer: Immunic AG
/ Key word(s): Personnel
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
19.05.2026 / 12:30... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,950 | +0,85 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| CYBIN | 4,020 | +7,92 % | Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs | Dr. Kramer's 25 years' of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and TORONTO... ► Artikel lesen | |
| KYNTRA BIO | 5,800 | -4,92 % | Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update | Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the... ► Artikel lesen | |
| OUTLOOK THERAPEUTICS | 0,295 | +26,39 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Completed Formal Dispute Resolution Meeting with FDA regarding Complete Response Letter (CRL) for ONS-5010; Decision Expected This Month Continued expansion of LYTENAVA (bevacizumab gamma) in Europe... ► Artikel lesen | |
| KARYOPHARM | 6,700 | -2,19 % | Karyopharm Therapeutics Inc.: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment | - Completed Enrollment of Phase 3 XPORT-EC-042 Trial in Endometrial Cancer; Topline Data Expected Mid-2026 -
- Phase 3 SENTRY Results Selected for Late-Breaking... ► Artikel lesen | |
| BIOLINERX | 2,120 | +4,95 % | BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models | ||
| PROTALIX BIOTHERAPEUTICS | 1,746 | +0,69 % | Protalix BioTherapeutics, Inc. - 8-K, Current Report | ||
| EDESA BIOTECH | 9,300 | -1,59 % | Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results | TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases... ► Artikel lesen | |
| CAN-FITE BIOPHARMA | 3,410 | 0,00 % | Can-Fite-Aktie steigt nach Veröffentlichung positiver Arthrose-Studiendaten | ||
| SAGIMET BIOSCIENCES | 6,140 | +6,97 % | Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade | ||
| BRIACELL THERAPEUTICS | 3,180 | -4,22 % | BriaCell Therapeutics Corp.: BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+ | BriaCell expands push in women's health, building on Phase 2 success in advanced metastatic breast cancerBria-OVA+, BriaCell's next generation personalized immunotherapy candidate for ovarian cancer... ► Artikel lesen | |
| CINGULATE | 4,740 | +7,97 % | Cingulate reports Q1 results |
GENELUX CORPORATION gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,010 (-0,34 %) liegt der Kurs bei 2,920 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENELUX CORPORATION finden Sie auf Wallstreet Online.